9:41 AM ET
Earnings Call
▶ Call
Krystal Biotech Earnings Call: Key Takeaways
Krystal Biotech delivered strong Q3 revenue growth of 30% and profitability, though clinical timelines for several pipeline programs were pushed to 2027, prompting a $400 million share repurchase authorization.
- Call
- Nov 2, 2026, 8:30 AM ET